Modus Therapeutics | Evaluate

August 05, 2019

Plan B or bust for Glycomimetics

The failure of its lead sickle cell project forces Glycomimetics to pivot to a leukaemia asset, but the company’s approach has taken a huge blow.

August 24, 2018

Global Blood makes second sickle cell bet

April 12, 2018

Global Blood aims for sickle cell dominance

Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.

May 26, 2017

Therapy focus – not quite the hammer for sickle cell disease

June 16, 2016

Therapy focus – Sickle cell therapies creep closer to market

October 20, 2015

Interview – Karolinska focuses, but not on early-stage medtech